2021 Annual Business Report

The strength of an
integrated business model

img-small

Vaccine development at Valneva

"We take a unique, specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution"

Juan Carlos Jaramillo MD, Chief Medical Officer

R&D
Investments 2021

173.3m
Our clinical pipeline

Our clinical pipeline

Our current clinical pipeline includes differentiated assets that either target unmet medical need or that may have meaningful advantages relative to existing vaccine options.

 

Lyme disease – VLA15

Lyme disease – VLA15

VLA15 is the only vaccine in clinical development against Lyme disease, the most common tick-borne infection in the northern hemisphere.

Chikungunya  – VLA1553

Chikungunya – VLA1553

VLA1553 is a single injection vaccine against chikungunya, a mosquito-borne disease that is highly prevalent in tropical and subtropical regions.

COVID-19 – VLA2001

COVID-19 – VLA2001

VLA2001 is the only COVID-19 inactivated and adjuvanted whole-virus vaccine currently in clinical development in Europe.

Our-commercial-business-2021-Anime

European Manufacturing Network

European Manufacturing Network

Our manufacturing base in Europe provides a long-term and sustainable industrial network to supply commercial and clinical products. We operate three manufacturing sites augmented by contract manufacturing partners.

Our Marketing & Distribution Structure

Our Marketing & Distribution Structure

Valneva has a specialist commercial infrastructure for the distribution of its travelers’ vaccines in key markets.

Franck GrimaudDirecteur Général & Chief Business Officer